Navigation Links
Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
Date:6/1/2009

elanoma patients have been observed - Regression of metastatic lesions in every site to which melanoma commonly spreads, including to the liver, lung and bone - Disease control lasting up to 14 months with continuous therapy, with many responding patients still receiving treatment - Interim median progression-free survival of at least six months

By contrast, no treatment response was observed in a small group of patients without the BRAF mutation, and progression-free survival was less than two months, consistent with historical data.

Drug-related adverse events, including rash and photosensitivity, have been classified as mild in grade. Serious adverse events, including diagnosis of cutaneous squamous cell carcinoma, were observed in some patients after chronic treatment; however the safety profile has been warranted favourable for this population and the trial authorised to proceed to the next stage of investigation.

The PLX4032 data not only represent an important step forward in understanding and treating malignant melanoma, but also represent a significant advance in the use of biomarkers and diagnostic tools and the potential benefits of tailoring cancer treatment to individual patients.

About Plexxikon

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company's clinical stage programs include PLX4032 for the treatment of melanoma and colorectal cancer, PLX5568 for the treatment of polycystic kidney disease and PLX204 for the treatment of diabetes. Among the company's preclinical development programs, candidates are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases as well as for the treatment of pancreatic and metastatic breast cancer.

Plexxik
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
2. Encouraging Gene Therapy Results in Genetic Form of Blindness
3. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
4. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
5. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
6. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
7. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
8. Actress and Mother Jennifer Garner Kicks Off American Lung Associations Faces of Influenza Awareness Campaign, Encouraging Families to Get Vaccinated Against Influenza
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
11. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Company ... programming expertise to big data, aerospace and defense, ... eInfochips, a leading engineering R&D services company, today ... NVIDIA GPU-powered solutions for aerospace and defense ... (HPC), industrial , and visual ...
(Date:7/29/2014)... Israel , July 30, 2014 /PRNewswire/ ... Premier, Stockholm : "IMNP."; "Immune" or ... screening of patients for a Phase II proof of ... bertilimumab in the treatment of moderate to severe bullous ... will receive two bertilimumab infusions, at a dose of ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
(Date:7/30/2014)... (PRWEB) July 30, 2014 Neil Haley, the ... Vi Millionaire GJ Reynolds to find out about what is ... create the best brand. , Reynolds is an original founding ... Star Ambassador, Vi Millionaire, and CEO of Simply G Media. ... Warrior Within You!" and holds the distinction of completing the ...
(Date:7/30/2014)... 2014 Pain Free Living web: ... for pain relief and improved performance. This new magnetic ... in a silicone core that is sheathed in nylon ... is embedded with scalar energy and Schumann frequency thus ... Living has 12 years experience developing magnetic bracelets. We ...
(Date:7/29/2014)... Cucamonga, CA (PRWEB) July 29, 2014 Paul ... Ways to Make More Money in 30 Days” E-book. The ... anyone can use to make extra cash. Examples include downloading ... utilizing unique free websites that help people monetize the assets ... and even unused items they can find in their garage. ...
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... to senior communities with focus on Brain Fitness ... Living in Ventura. Brain Fitness Program Director Tee ... to Aegis Memory Care unit and the Assisted ... sessions. Aegis Life Enrichment Director Christy Rozsa and ...
(Date:7/29/2014)... Daily Gossip indicates that the new method can ... that hemorrhoids commonly causes. The new method was developed ... , The author of H Miracle reveals that ... such as itching, burning, pain and swelling, as well ... Miracle by visiting the official website at: http://www.dailygossip.org/cure-hemorrhoids-in-48-hours-review-6851 ...
Breaking Medicine News(10 mins):Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
... , MONDAY, Jan.3 (HealthDay News) -- Two drugs ... may change the way the brain reacts to seeing someone ... how they cut cravings. Bupropion (Wellbutrin, Zyban) is prescribed ... it has not been clear how the drug does this. ...
... MONDAY, Jan. 3 (HealthDay News) People at higher risk ... new study findings show. Researchers at Washington University School ... U.S. alcoholism surveys conducted in 1991-1992 and 2001-2002. According to ... family history of alcoholism were 49 percent more likely to ...
... 15 years the U.S has seen a sharp increase in ... and 37 weeks, gestation. This is approximately 400,000 children each ... late-preterm infants are treated the same as full-term infants since ... is showing that this can be detrimental to a late-preterm ...
... Total Occlusion Summit and Left Main Coronary Interventions ... research findings and new developments in therapeutic procedures ... chronic total coronary occlusions and left main coronary ... When and why to open a chronic ...
... group to it at a specific site, a protein arrests ... research team led by scientists at The University of Texas ... Nature Cell Biology . In addition to highlighting ... deactivation of the enzyme called EZH2 is necessary for the ...
... Rockville, Md., January 3, 2011 For the first ... and appearance of prescription medication labels to reflect how ... on a national level. These labels can vary significantly ... to convey critical information for the safe use of ...
Cached Medicine News:Health News:Studies Decipher How Anti-Smoking Drugs Work 2Health News:Family History of Alcoholism May Raise Obesity Risk 2Health News:Care of late-preterm preemies may be insufficient 2Health News:Care of late-preterm preemies may be insufficient 3Health News:Protein wields phosphate group to inhibit cancer metastasis 2Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 2Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 3
Khosla Precision and Quality in Medical and Surgical Products....
...
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
Medicine Products: